TY - JOUR
T1 - Profile of serum bile acids in noncholestatic volunteers
T2 - Gender-related differences in response to fenofibrate
AU - Trottier, J.
AU - Caron, P.
AU - Straka, R. J.
AU - Barbier, O.
PY - 2011/8
Y1 - 2011/8
N2 - Fenofibrate belongs to the group of hypolipidemic fibrates that act as activators of the peroxisome proliferator-activated receptor-α (PPARα), which is a regulator of bile acid synthesis, metabolism, and transport. The present study aimed at evaluating the effects of fenofibrate on the circulating bile acid profile in humans. A study population of 200 healthy individuals comprising both genders completed a 3-week intervention with fenofibrate, and 17 bile acid species were measured in serum samples drawn before and after fenofibrate treatment. Fenofibrate caused significant reductions in levels of chenodeoxycholic (CDCA) (26.4%), ursodeoxycholic (UDCA) (30.5%), lithocholic (LCA) (18.4%), deoxycholic (DCA) (22.3%), and hyodeoxycholic (HDCA) (19.2%) acids. A gender-related difference was observed in the responses of various bile acids, and the total bile acid concentration was significantly reduced only in men (18.6%), whereas it remained almost unchanged in women (0.36%). This difference suggests that fenofibrate would be more efficient at reducing bile acid toxicity in men than in women in cholestatic liver diseases.
AB - Fenofibrate belongs to the group of hypolipidemic fibrates that act as activators of the peroxisome proliferator-activated receptor-α (PPARα), which is a regulator of bile acid synthesis, metabolism, and transport. The present study aimed at evaluating the effects of fenofibrate on the circulating bile acid profile in humans. A study population of 200 healthy individuals comprising both genders completed a 3-week intervention with fenofibrate, and 17 bile acid species were measured in serum samples drawn before and after fenofibrate treatment. Fenofibrate caused significant reductions in levels of chenodeoxycholic (CDCA) (26.4%), ursodeoxycholic (UDCA) (30.5%), lithocholic (LCA) (18.4%), deoxycholic (DCA) (22.3%), and hyodeoxycholic (HDCA) (19.2%) acids. A gender-related difference was observed in the responses of various bile acids, and the total bile acid concentration was significantly reduced only in men (18.6%), whereas it remained almost unchanged in women (0.36%). This difference suggests that fenofibrate would be more efficient at reducing bile acid toxicity in men than in women in cholestatic liver diseases.
UR - http://www.scopus.com/inward/record.url?scp=79960608008&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960608008&partnerID=8YFLogxK
U2 - 10.1038/clpt.2011.124
DO - 10.1038/clpt.2011.124
M3 - Article
C2 - 21716269
AN - SCOPUS:79960608008
SN - 0009-9236
VL - 90
SP - 279
EP - 286
JO - Clinical pharmacology and therapeutics
JF - Clinical pharmacology and therapeutics
IS - 2
ER -